Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

doi:10.1056/NEJMoa1902688

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

The New England journal of medicine - 31 Oct 2019

Perl Alexander E, Martinelli Giovanni, Cortes Jorge E, Neubauer Andreas, Berman Ellin, Paolini Stefania, Montesinos Pau, Baer Maria R, Larson Richard A, Ustun Celalettin, Fabbiano Francesco, Erba Harry P, Di Stasi Antonio, Stuart Robert, Olin Rebecca, Kasner Margaret, Ciceri Fabio, Chou Wen-Chien, Podoltsev Nikolai, Recher Christian, Yokoyama Hisayuki, Hosono Naoko, Yoon Sung-Soo, Lee Je-Hwan, Pardee Timothy, Fathi Amir T, Liu Chaofeng, Hasabou Nahla, Liu Xuan, Bahceci Erkut, Levis Mark J

Abstract excerpt

BACKGROUND: Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refr...

Topics

Administration, Oral
Adult
Aged
Aged, 80 and over
Aniline Compounds
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Follow-Up Studies

Humans

Leukemia, Myeloid, Acute

Liver

Male

Middle Aged

Mutation

Pyrazines

Recurrence

Source

Open in PubMed

Identifiers

PMID: 31665578
DOI: 10.1056/NEJMoa1902688

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-31665578-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.